Cardiff Oncology CEO buys stock and warrants
Cardiff Oncology, Inc. director and Chief Executive Officer Mani Mohindru reported open-market purchases on July 14, 2026.
Rhea-AI Filing Summary
Cardiff Oncology, Inc. director and Chief Executive Officer Mani Mohindru reported open-market purchases on July 14, 2026. She bought 34,364 shares of Common Stock at $1.455 per share and acquired 34,364 Common Stock Purchase Warrants exercisable at $1.33 per share. After these transactions, she holds 59,067 Common Shares directly and 34,364 warrants. The warrants become exercisable on the later of six months after issuance or the “Authorized Share Increase Date” and have a term of exercise of five and one-half years after the Initial Exercise Date.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 68,728 shares
Net Buy
2 txns
Insider
Mohindru Mani
Role
Chief Executive Officer
Bought
68,728 shs ($50K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock Purchase Warrant F1, F2 | 34,364 | $0.00 | $0.00 |
| Purchase | Common Stock | 34,364 | $1.455 | $50K |
Holdings After Transaction:
Common Stock Purchase Warrant — 34,364 contracts (Direct);
Common Stock — 59,067 shares (Direct)
Footnotes (2)
- F1. Exercisable beginning on the later of (i) six months after issuance or (ii) the Authorized Share Increase Date (the "Initial Exercise Date"). "Authorized Share Increase Date" means the date on which an amendment to the Issuer's certificate of incorporation increasing the number of authorized shares of its common stock to an amount sufficient for the exercise in full of the Common Warrants is filed with and accepted by the State of Delaware, subject to approval of such amendment by its stockholders.
- F2. The term of exercise is equal to five and one-half years after the Initial Exercise Date.
Key Figures
Common shares purchased: 34,364 shares
Purchase price per share: $1.455 per share
Warrants acquired: 34,364 warrants
+5 more
8 metrics
Common shares purchased
34,364 shares
Open-market purchase of Cardiff Oncology common stock on July 14, 2026
Purchase price per share
$1.455 per share
Price paid for the 34,364 common shares bought on July 14, 2026
Warrants acquired
34,364 warrants
Common Stock Purchase Warrants acquired, each for one common share
Warrant exercise price
$1.33 per share
Conversion or exercise price of the Common Stock Purchase Warrants
Shares held after transaction
59,067 shares
Direct Cardiff Oncology common stock holdings after the reported purchases
Warrant exercisability delay
six months after issuance
One condition for the Initial Exercise Date of the warrants
Warrant term after Initial Exercise Date
five and one-half years
Duration during which the warrants may be exercised after becoming exercisable
Total securities exposure added
68,728 securities
Sum of common shares purchased and underlying shares for warrants acquired
Key Terms
Common Stock Purchase Warrant, Authorized Share Increase Date, Initial Exercise Date, certificate of incorporation
4 terms
Common Stock Purchase Warrant financial
"The reporting person acquired 34,364 Common Stock Purchase Warrant instruments."
A common stock purchase warrant is a tradable certificate that gives its holder the right to buy a company’s common shares at a fixed price for a set period. Think of it as a coupon that lets you buy stock later at today’s agreed price; it can amplify gains if the share price rises but also can increase the total number of shares outstanding, which may reduce existing owners’ percentage of the company. Investors watch warrants because they offer leveraged upside and can affect future share value and ownership.
Initial Exercise Date financial
"Exercisable beginning on the later of six months after issuance or the Authorized Share Increase Date (the "Initial Exercise Date")."
certificate of incorporation regulatory
"an amendment to the Issuer's certificate of incorporation increasing the number of authorized shares..."
A certificate of incorporation is an official government document that creates a corporation and records key facts such as its legal name, basic governance structure, and stock authorization—think of it as a company's birth certificate plus its basic rulebook. Investors care because it establishes the company’s legal existence, limits owners’ personal liability, and sets the framework for issuing shares and enforcing shareholder rights, which affects ownership, control and the company’s ability to raise capital.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Cardiff Oncology (CRDF) CEO Mani Mohindru buy on July 14, 2026?
On July 14, 2026, CEO Mani Mohindru purchased 34,364 Cardiff Oncology common shares at $1.455 per share and acquired 34,364 Common Stock Purchase Warrants with an exercise price of $1.33 per share, all in open-market transactions.
What are the key terms of the Cardiff Oncology (CRDF) warrants acquired by the CEO?
The acquired instruments are 34,364 Common Stock Purchase Warrants, each exercisable into one common share at an exercise price of $1.33. They become exercisable starting on the Initial Exercise Date and have a five and one-half year exercise term thereafter.
When can the newly acquired Cardiff Oncology (CRDF) warrants be exercised?
The warrants become exercisable on the “Initial Exercise Date,” defined as the later of six months after issuance or the Authorized Share Increase Date, when the company’s charter amendment increasing authorized common shares is filed and accepted, subject to stockholder approval.
How many total Cardiff Oncology (CRDF) securities did Mani Mohindru effectively add exposure to?
Mani Mohindru added exposure to 68,728 securities in total: 34,364 newly purchased common shares plus 34,364 Common Stock Purchase Warrants, each warrant being exercisable for one share of Cardiff Oncology common stock under the disclosed terms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
